Search for: "S.A. v. Review Board"
Results 1 - 20
of 205
Sort by Relevance
|
Sort by Date
10 Jun 2024, 5:33 am
According to case law, applicants typically face difficulties in demonstrating the inherent distinctiveness of non-conventional trade marks and this is testified by the fact that most cases pertaining to non-conventional trade marks, spanning from 2021 to 2024, deal with the issue of inherent distinctiveness.The significant departure test for distinctivenessFor a trade mark to possess distinctive character, it must serve to identify the goods in respect of which registration is applied for as… [read post]
13 Feb 2024, 9:58 am
RAI Strategic Holdings, Inc. v. [read post]
Don’t Judge a Range by its Cover: Federal Circuit Sides with Patentee on Written Description Support
11 Feb 2024, 9:43 am
RAI Strategic Holdings, Inc. v. [read post]
23 Jan 2024, 9:01 pm
A substantive year in review will be documented in ISS SCAS’ forthcoming “Top 100 U.S. [read post]
22 Jan 2024, 11:40 am
In Sisvel International S.A. v. [read post]
20 Jan 2024, 9:24 pm
First, we review the law of prosecutorial disqualification in Georgia. [read post]
1 Dec 2023, 8:29 am
Similarly, in Young v. [read post]
24 Nov 2023, 6:08 pm
For example, in Oil States, the court found that an adjudication of patentability between private parties by the Patent Trial and Appeal Board (PTAB) involved a public right, properly adjudicated by the agency.[12] Meanwhile, private rights, as a general matter, cannot be adjudicated by agencies. [read post]
24 Oct 2023, 11:15 am
Sisvel International S.A. [read post]
6 Oct 2023, 12:25 pm
A. v. [read post]
3 Oct 2023, 9:01 pm
July 3, 2023, settled) SEC v. [read post]
25 Sep 2023, 8:10 am
On September 1, 2023, in Sisvel International S.A. v. [read post]
6 Sep 2023, 12:44 pm
Sisvel International S.A. v. [read post]
1 Aug 2023, 4:27 pm
Governance: Information related to, inter alia, board diversity, corporate integrity, bribery and corruption, shareholder rights, or executive compensation.[1] Although ESG-type disclosures are generally voluntary for companies in the United States,[2] newly proposed regulations may change that as early as later this year. [read post]
3 Jul 2023, 3:00 am
Galderma S.A. submitted a petition for post-grant review of claims 1–10 of the ‘728 patent. [read post]
29 Jun 2023, 2:31 pm
This week in Medytox, Inc. v. [read post]
29 Jun 2023, 9:43 am
This week in Medytox, Inc. v. [read post]
18 May 2023, 8:01 am
The court granted review in six-time relisted case Carnahan v. [read post]
30 Apr 2023, 4:00 am
International Law/Banks: JurisdictionEurobank Ergasias S.A. v. [read post]
23 Mar 2023, 5:32 am
ANVISA’s current specific rule which establishes requirements for drugs’ labels – Board of Directors’ Rule #47 of 2009 – prohibits carve out. [read post]
